Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Marker Therapeutics Inc

MRKR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.18

▼ -4.84%

Market Cap $19.67M · Vol 7.26K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$19.67M

Micro Cap

Div Yield

N/A

EPS Growth

+24.89%

YoY

RSI (14)

51.14

Momentum

Beta

1.51

vs Market

52W High

$2.45

51.74% below

52W Low

$0.83

42.17% above

Volume

7.26K

Avg 13.34K

P/B

1.48

Price-to-book

ROE

N/A

Return on equity

Free Float

94.51%

Public shares

Shariah Compliance8 STANDARDS

✗ Marker Therapeutics Inc (MRKR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MRKR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.87%

-4.07%

-19.73%

-18.06%

YTD

-20.81%

+37.24%

-78.23%

-94.01%

Financials & Valuation

TTM · Annual

Total Revenue	$3.55M
Net Income	$-12,163,620.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-350.68%
Net Profit Margin	-342.96%
ROE	N/A
ROA · ROIC	-59.27% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	6.43
P/B	1.48
P/FCF	N/A
EPS Growth	+24.89%
Outstanding Shares	16.67M

Technical Indicators

50-Day SMA	$1.31
200-Day SMA	$1.44
RSI (14)	51.14
Beta	1.51
52-Week High	$2.45
52-Week Low	$0.83

Volume Today	7.26K
Avg Daily Volume (30D)	13.34K
Relative Volume	0.54x
Volatility (10D)	61.39
Volatility (30D)	78.39
Free Float	94.51%

Analyst Consensus

BUY

Current Price $1.18

Mean Target $7.87

52W Low$0.83 52W High$2.45

Current

Target

$0.83 $2.45

Current Analyst target

+566.67% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SKLLN7

ISINUS57055L2060

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.